TEMOZOLOMIDE

Generic: TEMOZOLOMIDE

Accord Healthcare Inc.Manufacturer
ORALRoute
TEMOZOLOMIDEActive Substance
2017-02-27Original Approval

TEMOZOLOMIDE is FDA application ANDA201528, sponsored by ACCORD HLTHCARE. Any recalls listed below come from FDA drug enforcement reports, and reaction counts are the number of FAERS adverse event reports that mention the drug and that reaction; a report does not prove the drug caused it.

Recalls

Class II2026-03-03
Product label: Temozolomide Capsules, 5mg, packaged in 5-capsule bottles, Rx only, Manufactured for: Rising Pharmaceutic

Failed Impurities/Degradation Specifications: An out-of-specification result observed during 9th-mon

Class II2019-07-16
Temozolomide Capsules, 180 mg, packaged in a) 5-count bottle (NDC 67877-541-07), b) 14-count bottle (NDC 67877-541-14),

CGMP Deviations: product was manufactured that did not prevent possible cross contamination with bet

Class II2019-07-16
Temozolomide Capsules, 100 mg, packaged in a) 5-count bottle (NDC 67877-539-07), b) 14-count bottle (NDC 67877-539-14),

CGMP Deviations: product was manufactured that did not prevent possible cross contamination with bet

Class II2019-07-16
Temozolomide Capsules, 20 mg, packaged in a) 5-count bottle (NDC 67877-538-07), b) 14-count bottle (NDC 67877-538-14), R

CGMP Deviations: product was manufactured that did not prevent possible cross contamination with bet

Class II2019-07-16
Temozolomide Capsules, 250 mg, 5-count bottle, Rx only, Manufactured by: Deva Holding A.S., 1 Merkez Mahallesi, Istanbul

CGMP Deviations: product was manufactured that did not prevent possible cross contamination with bet

Class II2019-07-16
Temozolomide Capsules, 140 mg, packaged in a) 5-count bottle (NDC 67877-540-07), b) 14-count bottle (NDC 67877-540-14),

CGMP Deviations: product was manufactured that did not prevent possible cross contamination with bet

Class II2019-07-16
Temozolomide Capsules, 5 mg, packaged in a) 5-count bottle (NDC 67877-537-07), b) 14-count bottle (NDC 67877-537-14), Rx

CGMP Deviations: product was manufactured that did not prevent possible cross contamination with bet

Top Reported Reactions

1
DISEASE PROGRESSION
1,649 reports
2
DEATH
1,407 reports
3
THROMBOCYTOPENIA
1,357 reports
4
OFF LABEL USE
1,308 reports
5
DRUG INEFFECTIVE
1,078 reports
6
NAUSEA
997 reports
7
NEUTROPENIA
898 reports
8
MALIGNANT NEOPLASM PROGRESSION
771 reports
9
FEBRILE NEUTROPENIA
765 reports
10
VOMITING
753 reports